<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870933</url>
  </required_header>
  <id_info>
    <org_study_id>LB.02.01/VII/086/KEP.007.EV</org_study_id>
    <nct_id>NCT02870933</nct_id>
  </id_info>
  <brief_title>Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery</brief_title>
  <official_title>The Effect of Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation to Myocardial Perfusion in Patient Following Coronary Artery Bypass Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cardiovascular Center Harapan Kita Hospital Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cardiovascular Center Harapan Kita Hospital Indonesia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart Failure has several etiologies and one of them is coronary artery disease. Coronary
      artery bypass grafting (CABG) is one of revascularizations method which has been used for
      decades in coronary artery disease theraphy. However, data about coronary artery bypass
      grafting shows that post-CABG patients still have low ejection fraction. For the last decade,
      there have been a lot of studies about the using of stem cells to increase heart
      contractility and reverse the heart remodelling process. In this study, we use CD 133+ bone
      marrow stem cells which has been proved to have higher angiogenesis potential. The stem cells
      is given during CABG by injection transepicardial and transseptal. The purpose of this study
      is to determine whether transpicardial and transseptal injection of CD 133+ bone marrow stem
      cells can improve myocardial perfusion in patient with low ejection fraction following CABG
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study sample : patient with low ejection fraction indicated for CABG surgery in NCCHK who
      fulfill inclusion and exclusion criteria

      Sampling method : first we use consecutive method to find subject with male sex and age
      40-70. After that, we use simple random sampling to allocate each subject to each group.

      Total samples is 13 for each group. To anticipated drop out rate 10%, total sample is 15 for
      each group.

      Intervention and measurement :

      Control group will only receive CABG surgery. Study group will receive CBAG surgery and stem
      cell implantation. Stem cell aspiration will be performed 1 day before CABG procedure. Before
      aspiration, patients will be given local anesthetic and light sedation. Stem cell will be
      collected from posterior iliac crest. Total aspirate 190 cc. Stem cell CD133+ will be
      separated using CliniMACSÂ® Magnetic Separation Device after labelled with Magnetic microbeads
      - anti CD133 labelling.

      Myocardial perfusion reserve index will be measure using MRI. MPRI value will be obtained
      globally and segmentally in each 16 ventricle segments VEGF plasma level will be measured
      using sandwich Enzyme-linked Immunosorbent Assay method.

      Ejection fraction, left ventricle dimension, and scar size will be measured using MRI.

      Quality of life will be measured using Minnesota Living With Heart Failure Questionnaire.

      Statistical analysis is done using IBM SPSS Statistics version 21.0 (SPSS inc, Chicago, IL,
      USA). Numerical data will be presented in either mean/standard deviation or median/min-max
      depend on distribution of data. Hypothesis test for numeric variable is done using
      paired/non-paired T test or Mann-Whitney/Wilcoxon depend on normality of data. Normality test
      is done using Shapiro-Wilk test. Hypothesis test for category varible is done using
      chi-square or fischer test.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial perfusion</measure>
    <time_frame>6 months</time_frame>
    <description>Measured using myocardial perfusion reserve index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricle ejection fraction</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life will be measured using Minnesota Living With Heart Failure Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wall motion abnormality</measure>
    <time_frame>6 months</time_frame>
    <description>Wall motion abnormality will be measured using Wall Motion Score Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>scar size</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF plasma level</measure>
    <time_frame>6 months</time_frame>
    <description>VEGF plasma level will be measured using sandwich ELISA method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricle dimension</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>subject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this arm will receive Transepicardial with Transseptal CD 133+ Implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>this arm will not receive Transepicardial with Transseptal CD 133+ Implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Transepicardial with Transseptal CD 133+ Implantation</intervention_name>
    <description>Transepicardial with Transseptal CD 133+ Implantation</description>
    <arm_group_label>subject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with coronary artery disease 3 vessels disease indicated for CABG

          -  LVEF &lt; 35% which has been confirmed by MRI

          -  Patients with akinetic or hypokineic segment, and left ventricle myocardial
             hypoperfusion confirmed in MRI

          -  has signed informed consent

        Exclusion Criteria:

        Emergency CABG Ungraftable coronary artery Acute myocardial Infarct (&lt;14 days) Valve
        disease which need surgery repair Contraindicated for MRI High degree ventricular arrhytmia
        Coagulation disorder HIV positive patient, Hepatitis B + patients, HCV + patients AST/ALT &gt;
        1,5 upper normal value Creatinine &gt; 2 g/dl. Malignancy

        Drop out criteria :

        Aortic cross clamp &gt;120 minutes and CABG total time &gt;180
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tri Wisesa Soetisna, MD, MHA</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cardiovascular Center Harapan Kita</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tri Wisesa Soetisna, MD , MHA</last_name>
    <phone>+6281282827000</phone>
    <email>tricts2000@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cardiovascular Center Harapan Kita</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>11420</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tri Wssesa Soetisna, MD , MHA</last_name>
      <phone>+6281282827000</phone>
      <email>tricts2000@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cardiovascular Center Harapan Kita Hospital Indonesia</investigator_affiliation>
    <investigator_full_name>Tri Wisesa Soetisna, MD, MHA</investigator_full_name>
    <investigator_title>Director of Human Capital and General Affairs of National Cardiac Center</investigator_title>
  </responsible_party>
  <keyword>CD 133+</keyword>
  <keyword>Transepicardial with Transseptal Implantation</keyword>
  <keyword>CABG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

